
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
View the Pharmaceutical Executive March 2025 issue in an interactive format.
Click
over 1 year ago
High Impactover 1 year ago
Mark Frohlich: A ‘Natural’ Leaderover 1 year ago
FDA’s New Accelerated Approval Draft Guidanceover 1 year ago
The Virtual Reality of Modern Pharma Sales and Marketing





